ATE519759T1 - Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren - Google Patents

Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren

Info

Publication number: ATE519759T1
Authority: AT; Austria
Prior art keywords: alkyl; methods; nr15r16; compounds; halo
Prior art date: 2004-12-30

Application number

AT05855893T

Other languages

English (en)

Inventor

Jeff Chen

Meyr Lisa Dalrymple

Sergey Epshteyn

Timothy Forsyth

Tai Huynh

Mohamed Ibrahim

James Leahy

Gary Lewis

Grace Mann

Larry Mann

Robin Noguchi

Brian Ridgway

Joan Sangalang

Kevin Schnepp

Xian Shi

Craig Takeuchi

Matthew Williams

John Nuss

Atwood Cheung

Original Assignee

Exelixis Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-30

Filing date

2005-12-28

Publication date

2011-08-15

2005-12-28 Application filed by Exelixis Inc filed Critical Exelixis Inc

2011-08-15 Application granted granted Critical

2011-08-15 Publication of ATE519759T1 publication Critical patent/ATE519759T1/de

Links

108091000080 Phosphotransferase Proteins 0.000 title abstract 4
238000000034 method Methods 0.000 title abstract 4
102000020233 phosphotransferase Human genes 0.000 title abstract 4
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
150000001875 compounds Chemical class 0.000 abstract 6
102000001253 Protein Kinase Human genes 0.000 abstract 2
230000001413 cellular effect Effects 0.000 abstract 2
230000000694 effects Effects 0.000 abstract 2
125000005843 halogen group Chemical group 0.000 abstract 2
230000005764 inhibitory process Effects 0.000 abstract 2
108060006633 protein kinase Proteins 0.000 abstract 2
125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
101150088952 IGF1 gene Proteins 0.000 abstract 1
JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
238000003782 apoptosis assay Methods 0.000 abstract 1
125000004429 atom Chemical group 0.000 abstract 1
230000012292 cell migration Effects 0.000 abstract 1
230000001419 dependent effect Effects 0.000 abstract 1
230000004069 differentiation Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000002255 enzymatic effect Effects 0.000 abstract 1
125000001475 halogen functional group Chemical group 0.000 abstract 1
125000001072 heteroaryl group Chemical group 0.000 abstract 1
125000005842 heteroatom Chemical group 0.000 abstract 1
125000000623 heterocyclic group Chemical group 0.000 abstract 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
238000013508 migration Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
230000005522 programmed cell death Effects 0.000 abstract 1
230000035755 proliferation Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
230000019491 signal transduction Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

AT05855893T 2004-12-30 2005-12-28 Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren ATE519759T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US64043904P	2004-12-30	2004-12-30
US70486305P	2005-08-01	2005-08-01
PCT/US2005/047402 WO2006074057A2 (en)	2004-12-30	2005-12-28	Pyrimidine derivatives as kinase modulators and method of use

Publications (1)

Publication Number	Publication Date
ATE519759T1 true ATE519759T1 (de)	2011-08-15

Family

ID=36644899

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05855893T ATE519759T1 (de)	2004-12-30	2005-12-28	Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren

Country Status (7)

Country	Link
US (1)	US8211929B2 (de)
EP (1)	EP1841760B1 (de)
JP (1)	JP5208516B2 (de)
AT (1)	ATE519759T1 (de)
AU (1)	AU2005322855B2 (de)
CA (1)	CA2590110C (de)
WO (1)	WO2006074057A2 (de)

Families Citing this family (156)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
DK1534286T3 (da)	2002-07-29	2010-04-26	Rigel Pharmaceuticals Inc	Fremgangsmåder til behandling eller forebyggelse af autoimmune sygdomme med 2,4-pyrimidindiamin-forbindelser
BRPI0413018B8 (pt)	2003-07-30	2021-05-25	Rigel Pharmaceuticals Inc	composto, e, uso de um composto
EP1841760B1 (de)	2004-12-30	2011-08-10	Exelixis, Inc.	Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren
JP4801096B2 (ja)	2005-01-19	2011-10-26	ライジェルファーマシューティカルズ，インコーポレイテッド	２，４−ピリミジンジアミン化合物のプロドラッグおよびそれらの使用
BRPI0606793A8 (pt)	2005-02-04	2018-03-13	Astrazeneca Ab	composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação e uso do mesmo, métodos para a inibição da atividade de trk, para o tratamento ou profilaxia de câncer e para a produção de um efeito anti-proliferativo em um animal de sangue quente, e, composição farmacêutica
US7297700B2 (en)	2005-03-24	2007-11-20	Renovis, Inc.	Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
US20070203161A1 (en)	2006-02-24	2007-08-30	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
US7491732B2 (en) *	2005-06-08	2009-02-17	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the JAK pathway
WO2007023382A2 (en) *	2005-08-25	2007-03-01	Pfizer Inc.	Pyrimidine amino pyrazole compounds, potent kinase inhibitors
US8604042B2 (en)	2005-11-01	2013-12-10	Targegen, Inc.	Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en)	2005-11-01	2012-03-13	Targegen, Inc.	Use of bi-aryl meta-pyrimidine inhibitors of kinases
RU2589878C2 (ru)	2005-11-01	2016-07-10	Таргеджен, Инк.	Би-арил-мета-пиримидиновые ингибиторы киназ
JP4653842B2 (ja)	2006-02-17	2011-03-16	ライジェルファーマシューティカルズ，インコーポレイテッド	自己免疫疾患を治療または予防するための２，４−ピリミジンジアミン化合物
US8962643B2 (en)	2006-02-24	2015-02-24	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the JAK pathway
MX2008016004A (es)	2006-06-15	2009-01-16	Boehringer Ingelheim Int	2-anilino-4-(heterociclo)amino-pirimidinas en calidad de inhibidores de la proteina quinasa c-alfa.
US20070293525A1 (en)	2006-06-15	2007-12-20	Djung Jane F	2-anilino-4-aminoalkyleneaminopyrimidines
JP2009541480A (ja) *	2006-06-30	2009-11-26	アストラゼネカアクチボラグ	癌の治療において有用なピリミジン誘導体
EP2043651A2 (de) *	2006-07-05	2009-04-08	Exelixis, Inc.	Verfahren zur verwendung von igf1r und abl-kinase-modulatoren
ATE497496T1 (de)	2006-10-19	2011-02-15	Rigel Pharmaceuticals Inc	2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
MX2009004426A (es)	2006-10-23	2009-08-12	Cephalon Inc	Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores alk y c-met.
US7803940B2 (en)	2006-11-24	2010-09-28	Takeda Pharmaceutical Company Limited	Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases
TW200838559A (en) *	2006-11-29	2008-10-01	Imclone Systems Inc	Insulin-like growth factor-1 receptor antagonists for modulation of weight and liposity
GEP20156282B (en) *	2006-12-08	2015-05-11	Irm Llc	Compounds and compositions as protein kinase inhibitors
DK2091918T3 (en) *	2006-12-08	2014-12-01	Irm Llc	Compounds and Compositions as Protein Kinase Inhibitors
EP2101759B1 (de)	2006-12-14	2018-10-10	Exelixis, Inc.	Verfahren zur verwendung von mek-hemmern
US7638541B2 (en)	2006-12-28	2009-12-29	Metabolex Inc.	5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
JP2010526048A (ja) *	2007-05-04	2010-07-29	アストラゼネカアクチボラグ	アミノ−チアゾリル−ピリミジン誘導体、および癌の治療のための該誘導体の使用
UA99459C2 (en) *	2007-05-04	2012-08-27	Астразенека Аб	9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
CA2683152A1 (en) *	2007-06-11	2008-12-18	Miikana Therapeutics, Inc.	Substituted pyrazole compounds
AR067354A1 (es)	2007-06-29	2009-10-07	Sunesis Pharmaceuticals Inc	Compuestos utiles como inhibidores de la raf quinasa
US7968536B2 (en)	2007-06-29	2011-06-28	Millennium Pharmaceuticals, Inc.	Heterocyclic compounds useful as RAF kinase inhibitors
BRPI0814294A2 (pt)	2007-07-19	2015-02-03	Metabolex Inc	Agonistas de receptor heterocíclico ligado a n para o tratamento do diabetes e de desordens metabólicas.
WO2009027736A2 (en) *	2007-08-27	2009-03-05	Astrazeneca Ab	2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer
US8440681B2 (en)	2007-08-28	2013-05-14	Irm Llc	2-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors
WO2009056886A1 (en) *	2007-11-01	2009-05-07	Astrazeneca Ab	Pyrimidine derivatives and their use as modulators of fgfr activity
WO2009143389A1 (en)	2008-05-21	2009-11-26	Ariad Pharmaceuticals, Inc.	Phosphorous derivatives as kinase inhibitors
US9273077B2 (en)	2008-05-21	2016-03-01	Ariad Pharmaceuticals, Inc.	Phosphorus derivatives as kinase inhibitors
CN102124000B (zh)	2008-06-17	2014-09-17	阿斯利康(瑞典)有限公司	吡啶化合物
US8445505B2 (en) *	2008-06-25	2013-05-21	Irm Llc	Pyrimidine derivatives as kinase inhibitors
PE20100087A1 (es) *	2008-06-25	2010-02-08	Irm Llc	Compuestos y composiciones como inhibidores de cinasa
CN102203083A (zh) *	2008-06-25	2011-09-28	Irm责任有限公司	作为激酶抑制剂的嘧啶衍生物
AU2009262068C1 (en) *	2008-06-27	2015-07-02	Celgene Car Llc	Heteroaryl compounds and uses thereof
US11351168B1 (en)	2008-06-27	2022-06-07	Celgene Car Llc	2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) *	2008-06-27	2012-12-25	Celgene Avilomics Research, Inc.	2,4-disubstituted pyrimidines useful as kinase inhibitors
AU2009290617B2 (en) *	2008-09-15	2015-05-14	Fundacion Ciencia Para La Vida	Methods and compositions for modulating Ire1, Src, and Abl activity
US8759362B2 (en) *	2008-10-24	2014-06-24	Purdue Pharma L.P.	Bicycloheteroaryl compounds and their use as TRPV1 ligands
EP2389372B1 (de)	2009-01-23	2015-09-09	Rigel Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur inhibierung des jak-pfades
ES2474490T3 (es)	2009-02-13	2014-07-09	Shionogi & Co., Ltd.	Derivados de triazina como antagonistas de receptores P2X3 y/o P2X2/3 y composición farmacéutica que los contiene
CA2760794C (en)	2009-05-05	2017-07-25	Dana Farber Cancer Institute	Egfr inhibitors and methods of treating disorders
MX2011012632A (es) *	2009-05-27	2012-03-06	Abbott Lab	Inhibidores de actividad de cinasa tipo pirimidina.
CN102459264A (zh) *	2009-05-27	2012-05-16	雅培制药有限公司	激酶活性的嘧啶抑制剂
EP2435435B1 (de)	2009-05-27	2014-01-29	AbbVie Inc.	Pyrimidinhemmer der kinaseaktivität
MX2011013325A (es) *	2009-06-10	2012-04-30	Abbott Lab	2-(lh-pirazol-4-ilamino)-pirimidina como inhibidores de cinasa.
WO2011018517A1 (en)	2009-08-14	2011-02-17	Boehringer Ingelheim International Gmbh	Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en)	2009-08-14	2015-01-13	Boehringer Ingelheim International Gmbh	Selective synthesis of functionalized pyrimidines
US20110053916A1 (en)	2009-08-14	2011-03-03	Vertex Pharmaceuticals Incorporated	Pyrimidine compounds as tuberculosis inhibitors
US8410127B2 (en)	2009-10-01	2013-04-02	Metabolex, Inc.	Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
EP2519517B1 (de)	2009-12-29	2015-03-25	Dana-Farber Cancer Institute, Inc.	Typ-ii-raf-kinase-hemmer
WO2011083391A2 (en)	2010-01-05	2011-07-14	Pfizer Inc.	Biomarkers for anti-igf-ir cancer therapy
CA2798578C (en)	2010-05-21	2015-12-29	Chemilia Ab	Novel pyrimidine derivatives
PL2576541T3 (pl)	2010-06-04	2016-10-31		Pochodne aminopirymidyny jako modulatory lrrk2
BR112012032248A2 (pt)	2010-06-23	2016-09-13	Metabolex Inc	composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
PT2603081T (pt)	2010-08-10	2017-01-13	Celgene Avilomics Res Inc	Sal de besilato de um inibidor de btk
US9212130B2 (en)	2010-08-10	2015-12-15	Shionogi & Co., Ltd.	Heterocyclic derivative and pharmaceutical composition comprising the same
MX346367B (es)	2010-08-10	2017-03-16	Shionogi & Co Ltd *	Derivado de triazina y composicion farmaceutica que tiene actividad analgesica que comprende el mismo.
BR112013010564B1 (pt)	2010-11-01	2021-09-21	Celgene Car Llc	Compostos heterocíclicos e composições compreendendo os mesmos
ES2635713T3 (es)	2010-11-01	2017-10-04	Celgene Car Llc	Compuestos de heteroarilo y usos de los mismos
AU2010363329A1 (en)	2010-11-07	2013-05-09	Targegen, Inc.	Compositions and methods for treating myelofibrosis
EP2637502B1 (de)	2010-11-10	2018-01-10	Celgene CAR LLC	Mutanten-selektive egfr-hemmer und verwendungen davon
HUE046617T2 (hu) *	2010-11-10	2020-03-30	Genentech Inc	Pirazol-aminopirimidin-származékok mint LRRK2 modulátorok
US8546443B2 (en) *	2010-12-21	2013-10-01	Boehringer Ingelheim International Gmbh	Benzylic oxindole pyrimidines
US20140037642A1 (en)	2011-02-02	2014-02-06	Amgen Inc.	Methods and compositions relating to inhibition of igf-1r
AU2012230229A1 (en)	2011-03-24	2013-10-10	Noviga Research Ab	Novel pyrimidine derivatives
JP5999177B2 (ja)	2011-05-04	2016-09-28	アリアド・ファーマシューティカルズ・インコーポレイテッド	Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
WO2013026914A1 (en) *	2011-08-25	2013-02-28	F. Hoffmann-La Roche Ag	Serine/threonine pak1 inhibitors
TW201325593A (zh)	2011-10-28	2013-07-01	Celgene Avilomics Res Inc	治療布魯頓（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶疾病或病症之方法
EP2776042B1 (de)	2011-11-11	2019-03-20	Duke University	Wirkstoffkombinationstherapie zur behandlung von soliden tumoren
US9382239B2 (en)	2011-11-17	2016-07-05	Dana-Farber Cancer Institute, Inc.	Inhibitors of c-Jun-N-terminal kinase (JNK)
WO2013092940A1 (en)	2011-12-22	2013-06-27	F. Hoffmann-La Roche Ag	2, 4-diamine-pyrimidine derivative as serine/threonine kinase inhibitors
JP6124351B2 (ja)	2012-02-09	2017-05-10	塩野義製薬株式会社	複素環および炭素環誘導体
GB201204384D0 (en) *	2012-03-13	2012-04-25	Univ Dundee	Anti-flammatory agents
CN104302178B (zh)	2012-03-15	2018-07-13	西建卡尔有限责任公司	表皮生长因子受体激酶抑制剂的固体形式
EP2825042B1 (de)	2012-03-15	2018-08-01	Celgene CAR LLC	Salze eines epidermalen wachstumsfaktor-rezeptor-kinase-hemmers
CN104271569B (zh) *	2012-05-03	2016-08-24	霍夫曼-拉罗奇有限公司	作为lrrk2调节剂的吡唑氨基嘧啶衍生物
JP6469567B2 (ja)	2012-05-05	2019-02-13	アリアド・ファーマシューティカルズ・インコーポレイテッド	Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
US8980259B2 (en)	2012-07-20	2015-03-17	Novartis Ag	Combination therapy
WO2014063068A1 (en)	2012-10-18	2014-04-24	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 (cdk7)
USRE48175E1 (en)	2012-10-19	2020-08-25	Dana-Farber Cancer Institute, Inc.	Hydrophobically tagged small molecules as inducers of protein degradation
RU2674249C2 (ru) *	2012-11-05	2018-12-06	НэнтБайо, Инк.	Замещенные производные индол-5-ола и их терапевтическое применение
WO2014100748A1 (en)	2012-12-21	2014-06-26	Celgene Avilomics Research, Inc.	Heteroaryl compounds and uses thereof
CN103202843B (zh) *	2012-12-31	2015-04-29	刘强	一种嘧啶衍生物在制备预防和/或治疗和/或辅助治疗癌症的药物中的用途
CA2900012A1 (en)	2013-02-08	2014-08-14	Celgene Avilomics Research, Inc.	Erk inhibitors and uses thereof
JP2016514703A (ja)	2013-03-15	2016-05-23	ナントバイオサイエンス、インコーポレイテッド	置換インドール−５−オール誘導体及びそれらの治療適用
US9611283B1 (en)	2013-04-10	2017-04-04	Ariad Pharmaceuticals, Inc.	Methods for inhibiting cell proliferation in ALK-driven cancers
TWI637949B (zh)	2013-06-14	2018-10-11	塩野義製藥股份有限公司	胺基三衍生物及含有其等之醫藥組合物
US9492471B2 (en)	2013-08-27	2016-11-15	Celgene Avilomics Research, Inc.	Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
CN105849099B (zh)	2013-10-18	2020-01-17	达纳-法伯癌症研究所股份有限公司	周期蛋白依赖性激酶7(cdk7)的多环抑制剂
CA2927917C (en)	2013-10-18	2022-08-09	Syros Pharmaceuticals, Inc.	Heteroaromatic compounds useful for the treatment of proliferative diseases
US9415049B2 (en)	2013-12-20	2016-08-16	Celgene Avilomics Research, Inc.	Heteroaryl compounds and uses thereof
CN104926795B (zh) *	2014-03-17	2017-11-10	广东东阳光药业有限公司	取代的杂芳基化合物及其组合物和用途
US9394281B2 (en)	2014-03-28	2016-07-19	Calitor Sciences, Llc	Substituted heteroaryl compounds and methods of use
CN106536503B (zh) *	2014-04-18	2019-09-06	北京澳合药物研究院有限公司	一种酪氨酸激酶抑制剂及其用途
US10017477B2 (en)	2014-04-23	2018-07-10	Dana-Farber Cancer Institute, Inc.	Janus kinase inhibitors and uses thereof
AU2015292818B2 (en)	2014-07-21	2020-01-16	Dana-Farber Cancer Institute, Inc.	Imidazolyl kinase inhibitors and uses thereof
DK3172213T3 (da)	2014-07-21	2021-12-13	Dana Farber Cancer Inst Inc	Makrocykliske kinasehæmmere og anvendelser deraf
PL3177612T3 (pl)	2014-08-04	2022-08-08	Nuevolution A/S	Opcjonalnie skondensowane pochodne pirymidyny podstawione heterocyklilem, użyteczne w leczeniu chorób zapalnych, metabolicznych, onkologicznych i autoimmunologicznych
AU2015300782B2 (en)	2014-08-08	2020-04-16	Dana-Farber Cancer Institute, Inc.	Uses of salt-inducible kinase (SIK) inhibitors
TW201613892A (en)	2014-08-13	2016-04-16	Celgene Avilomics Res Inc	Forms and compositions of an ERK inhibitor
CN105461694B (zh) *	2014-09-27	2019-05-24	广东东阳光药业有限公司	取代的杂芳基化合物及其组合物和用途
PT3604294T (pt)	2014-10-13	2021-07-29	Yuhan Corp	Compostos e composições para modular atividades da cinase do mutante de egfr
ES2699948T3 (es)	2014-10-14	2019-02-13	Sunshine Lake Pharma Co Ltd	Compuestos de heteroarilo sustituido y métodos de uso
AU2015371251B2 (en)	2014-12-23	2020-06-11	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN104817553B (zh) *	2015-03-13	2018-11-09	华东师范大学	一种芳香基-杂环取代的嘧啶二胺类化合物及其衍生物及其医药用途
EP3273966B1 (de)	2015-03-27	2023-05-03	Dana-Farber Cancer Institute, Inc.	Hemmer von cyclinabhängigen kinasen
US10702527B2 (en)	2015-06-12	2020-07-07	Dana-Farber Cancer Institute, Inc.	Combination therapy of transcription inhibitors and kinase inhibitors
EP3347018B1 (de)	2015-09-09	2021-09-01	Dana-Farber Cancer Institute, Inc.	Hemmer von cyclinabhängigen kinasen
EP3347097B1 (de)	2015-09-11	2021-02-24	Sunshine Lake Pharma Co., Ltd.	Substituierte aminopyrimidin-derivate als modulatoren der kinasen jak, flt3 und aurora
WO2017129763A1 (en)	2016-01-28	2017-08-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
US11203576B2 (en)	2016-03-11	2021-12-21	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Aurora kinase and Janus kinase inhibitors for prevention of graft versus host disease
SG11201809342YA (en) *	2016-04-28	2018-11-29	Theravance Biopharma R&D Ip Llc	Pyrimidine compounds as jak kinase inhibitors
AU2017275657B2 (en)	2016-06-02	2021-08-19	Novartis Ag	Potassium channel modulators
IL299415B2 (en)	2016-06-16	2025-09-01	Denali Therapeutics Inc	Pyrimidine-2-ylamino-1H-pyrazoles as LRRK2 inhibitors for use in the treatment of neurodegenerative disorders
WO2018009544A1 (en)	2016-07-05	2018-01-11	The Broad Institute, Inc.	Bicyclic urea kinase inhibitors and uses thereof
AU2017305392A1 (en)	2016-08-03	2019-02-21	Cymabay Therapeutics, Inc.	Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
US11241435B2 (en)	2016-09-16	2022-02-08	The General Hospital Corporation	Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis
JOP20190080A1 (ar)	2016-10-14	2019-04-11	Bayer Pharma AG	مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها
WO2018136917A1 (en)	2017-01-23	2018-07-26	Cadent Therapeutics, Inc.	Potassium channel modulators
KR20190120331A (ko)	2017-02-28	2019-10-23	더 제너럴 하스피탈 코포레이션	Sik 억제제로서의 피리미도피리미디논의 용도
CN111683662B (zh) *	2017-08-28	2024-04-02	陈志宏	取代嘧啶类化合物及其药物组合物和治疗方法
EP3710006A4 (de)	2017-11-19	2021-09-01	Sunshine Lake Pharma Co., Ltd.	Substituierte heteroarylverbindungen und verfahren zur verwendung
WO2020005807A1 (en)	2018-06-25	2020-01-02	Dana-Farber Cancer Institute, Inc.	Taire family kinase inhibitors and uses thereof
US11066404B2 (en)	2018-10-11	2021-07-20	Incyte Corporation	Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
EP3870291A1 (de)	2018-10-22	2021-09-01	Cadent Therapeutics, Inc.	Kristalline formen von kaliumkanalmodulatoren
CN111601804B (zh) *	2018-11-27	2024-06-04	江苏豪森药业集团有限公司	含氮杂芳类衍生物调节剂、其制备方法和应用
JP7660063B2 (ja)	2018-12-28	2025-04-10	ダナ－ファーバーキャンサーインスティテュート，インコーポレイテッド	サイクリン依存性キナーゼ７のインヒビターおよびそれらの使用
US11384083B2 (en)	2019-02-15	2022-07-12	Incyte Corporation	Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
WO2020180959A1 (en)	2019-03-05	2020-09-10	Incyte Corporation	Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
US11919904B2 (en)	2019-03-29	2024-03-05	Incyte Corporation	Sulfonylamide compounds as CDK2 inhibitors
US11440914B2 (en)	2019-05-01	2022-09-13	Incyte Corporation	Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en)	2019-05-01	2022-09-20	Incyte Corporation	Tricyclic amine compounds as CDK2 inhibitors
MX2022001940A (es)	2019-08-14	2022-05-10	Incyte Corp	Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2.
CN115298177B (zh)	2019-10-11	2025-01-17	因赛特公司	作为cdk2抑制剂的双环胺
US11447479B2 (en)	2019-12-20	2022-09-20	Nuevolution A/S	Compounds active towards nuclear receptors
NZ786543A (en)	2019-12-20	2026-01-30	Nuevolution As	Compounds active towards nuclear receptors
CA3174252A1 (en)	2020-03-31	2021-10-07	Nuevolution A/S	Compounds active towards nuclear receptors
CA3174176A1 (en)	2020-03-31	2021-10-07	Sanne Schroder Glad	Compounds active towards nuclear receptors
BR112023003517A2 (pt) *	2020-08-26	2023-05-09	Nalo Therapeutics	Moduladores da proteína proto-oncogênica da família myc
CN112225729B (zh) *	2020-11-04	2022-02-01	四川大学华西医院	嘧啶类衍生物、其制备方法和应用以及药物组合物
CN113185428B (zh) *	2021-05-10	2022-07-15	安徽省庆云医药股份有限公司	一种4-甲基-3-氧代戊腈的合成方法
US11981671B2 (en)	2021-06-21	2024-05-14	Incyte Corporation	Bicyclic pyrazolyl amines as CDK2 inhibitors
US12084453B2 (en)	2021-12-10	2024-09-10	Incyte Corporation	Bicyclic amines as CDK12 inhibitors
US11976073B2 (en)	2021-12-10	2024-05-07	Incyte Corporation	Bicyclic amines as CDK2 inhibitors
EP4482833A4 (de) *	2022-02-23	2026-03-04	Repare Therapeutics Inc	Polo-like-kinase-4-(plk4)-inhibitoren, pharmazeutische zusammensetzungen, verfahren zur herstellung und verwendungen davon
WO2023164612A1 (en) *	2022-02-25	2023-08-31	Nalo Therapeutics	Modulators of myc family proto-oncogene protein
WO2024186827A2 (en) *	2023-03-06	2024-09-12	The Regents Of The University Of California	Novel host-directed therapeutic agent for the treatment of infectious diseases

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR9908004A (pt)	1998-02-17	2001-12-18	Tularik Inc	Composto, composição e método para prevençãoou supressão de uma infecção viral
GB9828511D0 (en)	1998-12-24	1999-02-17	Zeneca Ltd	Chemical compounds
DE19917785A1 (de)	1999-04-20	2000-10-26	Bayer Ag	2,4-Diamino-pyrimidin-Derivate
AU5020400A (en)	1999-05-20	2000-12-12	E.I. Du Pont De Nemours And Company	Heteroaryloxypyrimidine insecticides and acaricides
IL147395A0 (en)	1999-07-15	2002-08-14	Pharmacopeia Inc	Bradykinin b1 receptor antagonists
ITMI992711A1 (it)	1999-12-27	2001-06-27	Novartis Ag	Composti organici
AU3704101A (en)	2000-02-17	2001-08-27	Amgen Inc	Kinase inhibitors
GB0004888D0 (en) *	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0004890D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
AP2003002762A0 (en)	2000-09-15	2003-03-31	Vertex Pharma	Pyrazole compounds useful as protein kinase inhibitors
AU2002255452B2 (en)	2000-12-21	2006-06-08	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
US6939874B2 (en) *	2001-08-22	2005-09-06	Amgen Inc.	Substituted pyrimidinyl derivatives and methods of use
US7115617B2 (en) *	2001-08-22	2006-10-03	Amgen Inc.	Amino-substituted pyrimidinyl derivatives and methods of use
WO2003030909A1 (en)	2001-09-25	2003-04-17	Bayer Pharmaceuticals Corporation	2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
WO2003026666A1 (en)	2001-09-26	2003-04-03	Bayer Pharmaceuticals Corporation	2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors
SE0104140D0 (sv) *	2001-12-07	2001-12-07	Astrazeneca Ab	Novel Compounds
MY141867A (en)	2002-06-20	2010-07-16	Vertex Pharma	Substituted pyrimidines useful as protein kinase inhibitors
GB0226370D0 (en)	2002-11-12	2002-12-18	Novartis Ag	Organic compounds
DE602004021472D1 (en)	2003-02-20	2009-07-23	Smithkline Beecham Corp	Pyrimiidinverbindungen
US20050014753A1 (en)	2003-04-04	2005-01-20	Irm Llc	Novel compounds and compositions as protein kinase inhibitors
US7429596B2 (en)	2003-06-20	2008-09-30	The Regents Of The University Of California	1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
ES2328820T3 (es)	2003-10-17	2009-11-18	Astrazeneca Ab	Derivados de 4-(pirazol-3-ilamino)pirimidina para uso en el tratamiento de cancer.
MY141220A (en)	2003-11-17	2010-03-31	Astrazeneca Ab	Pyrazole derivatives as inhibitors of receptor tyrosine kinases
KR20060127032A (ko)	2004-01-09	2006-12-11	노파르티스 아게	Ｉｇｆ―ｉｒ 억제제로서의페닐-[4-(3-페닐-1ｈ-피라졸-4-일)-피리미딘-2-일]-아민유도체
JP2007223901A (ja) *	2004-03-24	2007-09-06	Takeda Chem Ind Ltd	複素環化合物およびその用途
TW200615268A (en) *	2004-08-02	2006-05-16	Osi Pharm Inc	Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
GB0419161D0 (en) *	2004-08-27	2004-09-29	Novartis Ag	Organic compounds
AU2005289426A1 (en)	2004-09-27	2006-04-06	Amgen Inc.	Substituted heterocyclic compounds and methods of use
EP1841760B1 (de)	2004-12-30	2011-08-10	Exelixis, Inc.	Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren

2005
- 2005-12-28 EP EP05855893A patent/EP1841760B1/de not_active Expired - Lifetime
- 2005-12-28 US US11/722,719 patent/US8211929B2/en not_active Expired - Fee Related
- 2005-12-28 AT AT05855893T patent/ATE519759T1/de not_active IP Right Cessation
- 2005-12-28 JP JP2007549634A patent/JP5208516B2/ja not_active Expired - Fee Related
- 2005-12-28 AU AU2005322855A patent/AU2005322855B2/en not_active Ceased
- 2005-12-28 CA CA2590110A patent/CA2590110C/en not_active Expired - Fee Related
- 2005-12-28 WO PCT/US2005/047402 patent/WO2006074057A2/en not_active Ceased

Also Published As

Publication number	Publication date
CA2590110A1 (en)	2006-07-13
AU2005322855A1 (en)	2006-07-13
US20080249079A1 (en)	2008-10-09
US8211929B2 (en)	2012-07-03
EP1841760A2 (de)	2007-10-10
AU2005322855B2 (en)	2012-09-20
JP5208516B2 (ja)	2013-06-12
WO2006074057A2 (en)	2006-07-13
WO2006074057A3 (en)	2006-10-26
EP1841760B1 (de)	2011-08-10
CA2590110C (en)	2014-06-03
JP2008526759A (ja)	2008-07-24

Legal Events

Date	Code	Title	Description
2012-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE519759T1 (de)	2011-08-15	Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren
WO2005040355A3 (en)	2005-08-04	Tao kinase modulators and methods of use
WO2005117909A3 (en)	2006-04-27	Kinase modulators and methods of use
MXPA05008878A (es)	2005-10-05	Derivados de aminotiazol sustituidos con cicloalquilo que contiene n y composiciones farmaceuticas para inhibir la proliferacion celular, y metodos para su uso.
EA200501332A1 (ru)	2006-06-30	Производные пиримидин-4-она и их применение в качестве модуляторов киназы p38
ATE543821T1 (de)	2012-02-15	Ä1h-pyrazoloä3,4-düpyrimidin-4-ylü-piperidin- oder piperazinverbindungen als serin-threonin- kinasemodulatoren (p70s6k, atk1 und atk2) zur behandlung von immunologischen, entzündlichen und proliferativen erkrankungen
EA201101566A1 (ru)	2012-05-30	Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ
PE20060479A1 (es)	2006-07-14	Compuestos heteroaril-aril-ureas como inhibidores de la quinasa
WO2005039506A3 (en)	2006-01-19	P70s6 kinase modulators and method of use
DE602004024988D1 (de)	2010-02-25	2-aminopyrimidin-derivate als raf-kinase-hemmer
LU92508I2 (fr)	2015-11-02	Cabozantinib et toutes les formes thérapeutiquement équivalentes qui en dérivent telles que protégées par le brevet de base, y compris les sels pharmacetuiquement acceptables
EA201001017A1 (ru)	2011-02-28	3h-[1,2,3]триазоло[4,5-d]пиримидиновые соединения, их применение в качестве ингибиторов киназы mtor и киназы pi3 и их синтезы
BRPI0810936B8 (pt)	2022-12-06	Composto, método para controle de uma praga invertebrada e uso de um composto de fórmula 1
NO20070555L (no)	2007-01-30	Kinazolinonderivater som parp-inhibitorer
NO20070557L (no)	2007-01-30	Ftalazinderivater som PARP-inhibitorer
CA2507100A1 (en)	2004-06-10	2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer
EA200970557A1 (ru)	2009-12-30	Соединения и композиции в качестве ингибиторов протеинкиназы
WO2005112932A3 (en)	2006-11-23	Raf modulators and methods of use
EA200870373A1 (ru)	2009-04-28	Пиридил- и пиримидинилзамещённые производные пиррола, тиофена и фурана в качестве ингибиторов киназ
AR077849A2 (es)	2011-09-28	Compuestos y composiciones como inhibidores de proteina quinasa
EA201071232A1 (ru)	2011-06-30	Триазины как ингибиторы киназы pi3 и mtor
UA116768C2 (uk)	2018-05-10	Дизаміщені бензотієнілпіролотриазини та їх застосування як інгібіторів кінази рфрф
NO20080163L (no)	2008-03-07	Aminopyrimidiner som kinasemodulatorer
PA8601901A1 (es)	2004-11-26	Pirazoles como inhibidores de factor de necrosis tumoral
WO2004091480A3 (en)	2005-08-11	Tie-2 modulators and methods of use